Stock Ideas
Stocks
Funds
Screener
Sectors
Watchlists
CRL

CRL - Charles River Laboratories International Stock Price, Fair Value and News

218.30USD-0.28 (-0.13%)Market Closed

Market Summary

CRL
USD218.30-0.28
Market Closed
-0.13%

CRL Stock Price

View Fullscreen

CRL RSI Chart

CRL Valuation

Market Cap

11.2B

Price/Earnings (Trailing)

25.3

Price/Sales (Trailing)

2.73

EV/EBITDA

13.09

Price/Free Cashflow

15.96

CRL Price/Sales (Trailing)

CRL Profitability

EBT Margin

15.15%

Return on Equity

12.21%

Return on Assets

5.45%

Free Cashflow Yield

6.26%

CRL Fundamentals

CRL Revenue

Revenue (TTM)

4.1B

Rev. Growth (Yr)

-1.73%

Rev. Growth (Qtr)

-0.19%

CRL Earnings

Earnings (TTM)

444.5M

Earnings Growth (Yr)

-29.26%

Earnings Growth (Qtr)

-61%

Breaking Down CRL Revenue

Last 7 days

1.0%

Last 30 days

4.1%

Last 90 days

-3.7%

Trailing 12 Months

7.0%

How does CRL drawdown profile look like?

CRL Financial Health

Current Ratio

1.75

Debt/Equity

0.73

Debt/Cashflow

0.26

CRL Investor Care

Shares Dilution (1Y)

0.64%

Diluted EPS (TTM)

8.52

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20244.1B000
20234.1B4.2B4.2B4.1B
20223.6B3.7B3.8B4.0B
20213.0B3.3B3.4B3.5B
20202.7B2.7B2.8B2.9B
20192.4B2.4B2.5B2.6B
20181.9B2.0B2.1B2.3B
20171.8B1.8B1.8B1.9B
20161.4B1.5B1.6B1.7B
20151.3B1.3B1.3B1.4B
20141.2B1.2B1.3B1.3B
20131.1B1.1B1.2B1.2B
20121.1B1.1B1.1B1.1B
20111.1B1.1B1.1B1.1B
20101.2B1.1B1.1B1.1B
200901.3B1.2B1.2B
20080001.3B
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed S&P 500 Index

Grufity's Fair Value model takes all the S&P 500 stocks and divides them into separate buckets based on their attractiveness. The 'Very Cheap' bucket of S&P 500 has greatly outperformed S&P 500 Index. Conversely, S&P500 stocks considered 'Very Expensive' by the model underperformed the S&P500 index in the past three years. Grufity Fair Value is available for 2300+ stocks, including 90% of S&P 500 stocks. Grufity's Fair Value Model separates high-return stocks from low-return stocks.

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $17,289
S&P 500 Index: $12,922
Very Expensive Stocks: $11,022


Grufity's Fair Value model does a great job in separating High Performing Stocks from Low Performing ones in the S&P 500 list.

S&P 500 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Charles River Laboratories International

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Jun 03, 2024
laplume joseph w
gifted
-
-
-311
evp, corp strategy & develop
May 31, 2024
creamer victoria l
acquired
-
-
1,967
evp & chief people officer
May 31, 2024
parisotto shannon m
acquired
-
-
1,727
cevp, disc & safety assessment
May 31, 2024
pease flavia
acquired
-
-
2,159
corporate executive vp & cfo
May 31, 2024
knell michael gunnar
acquired
-
-
648
csvp&chief accounting officer
May 31, 2024
laplume joseph w
acquired
-
-
2,111
evp, corp strategy & develop
May 31, 2024
girshick birgit
acquired
-
-
3,838
corporate executive vp & coo
May 29, 2024
laplume joseph w
sold (taxes)
-47,835
214
-223
evp, corp strategy & develop
May 29, 2024
parisotto shannon m
sold (taxes)
-23,596
214
-110
cevp, disc & safety assessment
May 29, 2024
girshick birgit
sold (taxes)
-46,334
214
-216
corporate executive vp & coo

1–10 of 50

Which funds bought or sold CRL recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Jul 19, 2024
China Universal Asset Management Co., Ltd.
unchanged
-
-5,729
18,386
-%
Jul 19, 2024
Raymond James Financial Services Advisors, Inc.
added
30.45
-8,116
1,484,280
-%
Jul 19, 2024
NISA INVESTMENT ADVISORS, LLC
added
13.83
-352,310
2,314,110
0.01%
Jul 19, 2024
OFI INVEST ASSET MANAGEMENT
new
-
1,021,580
1,021,580
0.03%
Jul 19, 2024
First Horizon Advisors, Inc.
reduced
-7.89
-24,527
57,841
-%
Jul 19, 2024
Sumitomo Mitsui Trust Holdings, Inc.
reduced
-8.31
-9,629,960
22,368,700
0.02%
Jul 19, 2024
Continuum Advisory, LLC
unchanged
-
-376
3,305
-%
Jul 19, 2024
Apollon Wealth Management, LLC
sold off
-100
-272,034
-
-%
Jul 19, 2024
Venturi Wealth Management, LLC
added
304
139,798
206,994
0.01%
Jul 19, 2024
HARBOR INVESTMENT ADVISORY, LLC
added
55.22
29,523
190,467
0.02%

1–10 of 50

Are Funds Buying or Selling CRL?

Are funds buying CRL calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own CRL
No. of Funds

Unveiling Charles River Laboratories International's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2024
vanguard group inc
11.66%
5,980,236
SC 13G/A
Jan 24, 2024
blackrock inc.
10.1%
5,195,086
SC 13G/A
Jul 07, 2023
blackrock inc.
10.2%
5,218,752
SC 13G/A
Feb 09, 2023
vanguard group inc
11.71%
5,956,960
SC 13G/A
Jan 31, 2023
fmr llc
-
0
SC 13G/A
Jan 24, 2023
blackrock inc.
9.8%
4,981,145
SC 13G/A
Feb 09, 2022
fmr llc
-
0
SC 13G
Feb 09, 2022
vanguard group inc
11.63%
5,869,125
SC 13G/A
Jan 28, 2022
blackrock inc.
10.1%
5,080,026
SC 13G/A
Feb 10, 2021
vanguard group inc
10.11%
5,027,904
SC 13G/A

Recent SEC filings of Charles River Laboratories International

View All Filings
Date Filed Form Type Document
Jun 04, 2024
4
Insider Trading
Jun 04, 2024
4
Insider Trading
Jun 04, 2024
4
Insider Trading
Jun 04, 2024
4
Insider Trading
Jun 04, 2024
4
Insider Trading
Jun 04, 2024
4
Insider Trading
Jun 03, 2024
4
Insider Trading
Jun 03, 2024
4
Insider Trading
May 31, 2024
4
Insider Trading
May 30, 2024
4
Insider Trading

Peers (Alternatives to Charles River Laboratories International)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
180.4B
23.7B
-5.41% 12.43%
40.98
7.6
-8.94% -35.91%
38.7B
3.7B
-7.03% -13.75%
44.62
10.38
8.57% 23.94%
38.5B
6.6B
-2.30% 5.82%
30.96
5.83
-6.38% -8.07%
16.2B
9.3B
6.34% 1.67%
19.17
1.75
-3.29% 6.68%
13.0B
2.0B
4.50% 70.57%
41.75
6.65
25.57% 21.62%
13.0B
1.2B
-1.84% 123.25%
-35.62
10.77
39.26% 33.08%
11.2B
4.1B
4.05% 7.02%
25.3
2.73
0.49% -10.45%
MID-CAP
8.6B
2.5B
11.64% -50.70%
-35.95
3.41
15.21% 53.51%
3.8B
603.7M
2.74% -17.56%
-8.17
6.23
25.21% 30.68%
3.5B
929.2M
-2.97% -26.96%
2.3K
3.81
28.93% 111.61%
SMALL-CAP
942.7M
275.1M
28.64% 80.46%
-5.15
3.43
-13.93% -126.97%
94.1M
31.1M
16.81% -87.36%
-1.22
3.02
0.95% 19.75%
18.8M
9.0M
-7.93% -45.09%
-1.28
2.09
4.46% 45.80%
393.9K
5.5M
-13.04% -71.63%
-0.03
0.07
-68.52% -143.74%
183.8K
-
-50.00% -94.83%
-0.01
0.01
- -

Charles River Laboratories International News

Latest updates
Defense World11 hours ago

Charles River Laboratories International Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Millions)
Income Statement (Quarterly)
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue-0.2%1,0121,0131,0271,0601,0291,100989973914905896915825791743683707691668658605
  S&GA Expenses-5.5%186197176200175200184132150144149172156143128128130130130136123
EBITDA Margin1.3%0.26*0.26*0.25*0.25*0.25*0.25*0.21*0.22*0.22*0.23*0.23*0.24*---------
Interest Expenses4.3%35.0034.0034.0035.0034.0035.0011.004.009.0012.0016.0016.0030.0033.0019.0019.0015.0024.006.0021.0010.00
Income Taxes24.2%25.0020.0025.0029.0027.0056.0025.0033.0016.0024.0018.0038.002.0028.0033.0016.005.0025.00-0.3215.0011.00
Earnings Before Taxes------------------10673.0059.0066.00
EBT Margin0.4%0.15*0.15*0.15*0.15*0.15*0.16*0.13*0.13*0.13*0.14*0.13*0.14*---------
Net Income-61.0%73.0018787.0097.0010318796.0010993.0013810388.0062.0014310367.0051.0080.0073.0044.0055.00
Net Income Margin-6.0%0.11*0.11*0.11*0.12*0.12*0.12*0.12*0.12*0.12*0.11*0.12*0.12*0.12*--------
Free Cashflow-41.2%130221205148109235133149103229175187170--------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets-0.5%8,1538,1957,6077,7727,6997,6037,3837,5297,0757,0247,0586,7205,8095,4915,2135,2415,2024,6934,5834,6253,927
  Current Assets3.7%1,6681,6091,4441,5051,4481,4391,4151,3931,3331,2741,3791,2681,4231,2011,1401,2351,2081,0219721,010866
    Cash Equivalents18.2%327277157200209241196207242246213223465233243402372240165201126
  Inventory-5.0%361380293285263256262257221199182194194186181168163161156135130
  Net PPE--------------1,124--1,0331,0441,0081,006907
  Goodwill-0.8%3,0703,0952,8852,9172,9022,8502,7762,8602162,7122,73624061272.001,7781,7361,7322101,522--
Liabilities-1.9%4,4494,5364,2564,4724,5434,5794,7114,8364,4044,4324,5944,3663,5933,3473,2883,4603,5223,0263,0183,1472,505
  Current Liabilities-9.5%9551,0559941,0089811,0921,0141,0489941,033984930803840787728691710682636530
  Long Term Debt0.5%2,6602,6472,5142,6782,7442,7082,9372,9972,6762,6642,8932,7272,2021,9301,9682,2072,3271,8501,8832,0401,541
Shareholder's Equity1.2%3,6403,5973,3063,2583,1142,9812,6332,6532,6152,5392,4322,3232,1882,1181,9011,7571,6561,6381,5361,4581,401
  Retained Earnings3.8%1,9601,8871,7201,6331,5361,4331,2801,1831,07498187977568762550139933128021414197.00
  Additional Paid-In Capital1.8%1,9391,9061,8771,8501,8301,8051,7811,7611,7451,7181,7201,6911,6601,6281,6141,5901,5631,5321,5151,4981,481
Shares Outstanding0.3%52.0051.0051.0051.0051.0051.0051.0051.0051.0050.0050.0050.00---------
Minority Interest6.0%6.005.005.006.005.005.006.005.005.004.005.005.004.004.005.004.004.003.004.003.003.00
Float----10,687---11,392---18,339---8,333---6,797-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations-41.2%129,888220,943205,450148,122109,383234,757132,779149,474102,630229,258174,722186,590170,229138,379177,300162,30668,590180,677155,847129,55314,859
  Share Based Compensation-14.3%16,73819,52122,79716,27013,46022,06921,99914,93014,61919,18522,02317,07713,18915,36816,87013,14310,96013,84214,02516,50512,899
Cashflow From Investing64.0%-85,792-238,371-79,557-76,609-168,61844,383-92,186-462,114-98,0059,307-355,050-954,193-137,996-88,423-70,810-28,626-413,685-70,871-61,393-528,425-20,813
Cashflow From Financing-85.2%18,346123,568-162,866-71,46425,241-248,956-51,594271,436-13,283-218,972178,895517,955194,720-59,229-268,639-104,096479,212-39,044-133,443473,507-69,083
  Buy Backs6627.3%9,35113938.004,96619,01215924.004,47433,9942671434,26936,02874.0011211823,67547.0015712317,760
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

CRL Income Statement

2024-03-30
CONDENSED CONSOLIDATED STATEMENTS OF INCOME (UNAUDITED) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Mar. 30, 2024
Apr. 01, 2023
Total revenue$ 1,011,560$ 1,029,373
Costs and expenses:  
Cost of revenue (excluding amortization of intangible assets)666,717651,719
Selling, general and administrative186,291174,846
Amortization of intangible assets32,57534,916
Operating income125,977167,892
Other income (expense):  
Interest income2,202806
Interest expense(35,001)(34,380)
Other income (expense), net5,833(3,277)
Income before income taxes99,011131,041
Provision for income taxes24,52927,087
Net income74,482103,954
Less: Net income attributable to noncontrolling interests1,522823
Net income available to Charles River Laboratories International, Inc.72,960103,131
Preferred Stock Dividends and Other Adjustments [Abstract]  
Net income available to Charles River Laboratories International, Inc.72,960103,131
Less: Adjustment of redeemable noncontrolling interest4010
Less: Incremental dividends attributable to noncontrolling interest holders5,2300
Net income available to Charles River Laboratories International, Inc. common shareholders$ 67,329$ 103,131
Net income attributable to common shareholders:  
Basic (in dollars per share)$ 1.31$ 2.02
Diluted (in dollars per share)$ 1.30$ 2.01
Weighted-average number of common shares outstanding:  
Basic (in shares)51,43751,097
Diluted (in shares)51,84251,428
Cost of services provided (excluding amortization of intangible assets)  
Total revenue$ 816,862$ 857,366
Costs and expenses:  
Cost of revenue (excluding amortization of intangible assets)578,164565,477
Cost of products sold (excluding amortization of intangible assets)  
Total revenue194,698172,007
Costs and expenses:  
Cost of revenue (excluding amortization of intangible assets)$ 88,553$ 86,242

CRL Balance Sheet

2024-03-30
CONDENSED CONSOLIDATED BALANCE SHEETS (UNAUDITED) - USD ($)
$ in Thousands
Mar. 30, 2024
Dec. 30, 2023
Current assets:  
Cash and cash equivalents$ 327,039$ 276,771
Trade receivables and contract assets, net of allowances for credit losses of $25,407 and $25,722, respectively786,980780,375
Inventories361,281380,259
Prepaid assets93,83487,879
Other current assets99,05483,378
Total current assets1,668,1881,608,662
Property, plant and equipment, net1,618,7081,639,741
Venture capital and strategic equity investments243,543243,811
Operating lease right-of-use assets, net384,394394,029
Goodwill3,070,2413,095,045
Intangible assets, net827,638864,051
Deferred tax assets36,92440,279
Other assets303,147309,383
Total assets8,152,7838,195,001
Current liabilities:  
Accounts payable129,682168,937
Accrued compensation189,606213,290
Deferred revenue256,383241,820
Accrued liabilities190,892227,825
Other current liabilities188,247203,210
Total current liabilities954,8101,055,082
Long-term debt, net and finance leases2,660,4592,647,147
Operating lease right-of-use liabilities418,054419,234
Deferred tax liabilities180,094191,349
Other long-term liabilities235,441223,191
Total liabilities4,448,8584,536,003
Commitments and contingencies (Notes 2, 11, 13, and 15)
Redeemable noncontrolling interest57,77556,722
Equity:  
Preferred stock, $0.01 par value; 20,000 shares authorized; no shares issued and outstanding00
Common stock, $0.01 par value; 120,000 shares authorized; 51,552 shares issued and 51,510 shares outstanding as of March 30, 2024, and 51,338 shares issued and outstanding as of December 30, 2023515513
Additional paid-in capital1,939,4131,905,578
Retained earnings1,959,7771,887,218
Treasury stock, at cost, 42 and zero shares, as of March 30, 2024 and December 30, 2023, respectively(9,351)0
Accumulated other comprehensive loss(249,919)(196,427)
Total Charles River Laboratories International, Inc. equity3,640,4353,596,882
Nonredeemable noncontrolling interests5,7155,394
Total equity3,646,1503,602,276
Total liabilities, noncontrolling interests and equity$ 8,152,783$ 8,195,001
CRL
Charles River Laboratories International, Inc., a non-clinical contract research organization, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodent research model strains and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening non-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of non-clinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies; and avian vaccine services that provide specific-pathogen-free (SPF) fertile chicken eggs, SPF chickens, and diagnostic products used to manufacture vaccines. The company also provides contract vivarium operation services to biopharmaceutical clients. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.
 CEO
 WEBSITEcriver.com
 INDUSTRYDiagnostics & Research
 EMPLOYEES20000

Charles River Laboratories International Frequently Asked Questions


What is the ticker symbol for Charles River Laboratories International? What does CRL stand for in stocks?

CRL is the stock ticker symbol of Charles River Laboratories International. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Charles River Laboratories International (CRL)?

As of Fri Jul 19 2024, market cap of Charles River Laboratories International is 11.25 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of CRL stock?

You can check CRL's fair value in chart for subscribers.

What is the fair value of CRL stock?

You can check CRL's fair value in chart for subscribers. The fair value of Charles River Laboratories International is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Charles River Laboratories International is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for CRL so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Charles River Laboratories International a good stock to buy?

The fair value guage provides a quick view whether CRL is over valued or under valued. Whether Charles River Laboratories International is cheap or expensive depends on the assumptions which impact Charles River Laboratories International's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for CRL.

What is Charles River Laboratories International's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jul 19 2024, CRL's PE ratio (Price to Earnings) is 25.3 and Price to Sales (PS) ratio is 2.73. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. CRL PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Charles River Laboratories International's stock?

In the past 10 years, Charles River Laboratories International has provided 0.151 (multiply by 100 for percentage) rate of return.